BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
64 results:

  • 1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
    Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
    Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic atr inhibition.
    Borenäs M; Umapathy G; Lind DE; Lai WY; Guan J; Johansson J; Jennische E; Schmidt A; Kurhe Y; Gabre JL; Aniszewska A; Strömberg A; Bemark M; Hall MN; Eynden JVD; Hallberg B; Palmer RH
    Proc Natl Acad Sci U S A; 2024 Jan; 121(1):e2315242121. PubMed ID: 38154064
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The atr inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
    Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic Value of
    Carlier T; Frécon G; Mateus D; Rizkallah M; Kraeber-Bodéré F; Kanoun S; Blanc-Durand P; Itti E; Le Gouill S; Casasnovas RO; Bodet-Milin C; Bailly C
    J Nucl Med; 2024 Jan; 65(1):156-162. PubMed ID: 37945379
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
    Molica S; Tam C; Allsup D; Polliack A
    Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
    Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
    Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma.
    Gong C; Wu J; Song W; Li H; Shi C; Gao Y; Shi Z; Li Z; Zhang M
    Ann Hematol; 2023 Oct; 102(10):2845-2855. PubMed ID: 37500898
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
    Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
    Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
    Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.
    Rades D; Segedin B; Schild SE; Lomidze D; Veninga T; Cacicedo J
    Radiat Oncol; 2022 Aug; 17(1):143. PubMed ID: 35978340
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
    Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
    Gao Y; Feng X; Song W; Li H; Shi C; Jin M; Li Z; Zhang L; Zhang M
    Hematol Oncol; 2022 Oct; 40(4):678-688. PubMed ID: 35439335
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck lymphoma.
    Yan S; Ma J; Yang M; Liu B; Li S; Yang L; Zhang Q; Li X
    Anal Cell Pathol (Amst); 2022; 2022():4936099. PubMed ID: 35242496
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Enhanced Cytotoxic Effects in B-Cell Leukemia and lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
    Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell lymphoma Treated with R-CHOP: A Prospective Cohort Study.
    Jeong SH; Kim SJ; Yoon DH; Park Y; Kang HJ; Koh Y; Lee GW; Lee WS; Yang DH; Do YR; Kim MK; Yoo KH; Choi YS; Yun HJ; Yi JH; Jo JC; Eom HS; Kwak JY; Shin HJ; Park BB; Hyun SY; Yi SY; Kwon JH; Oh SY; Kim HJ; Sohn BS; Won JH; Kim SH; Lee HS; Suh C; Kim WS
    Cancer Res Treat; 2022 Oct; 54(4):1268-1277. PubMed ID: 34990525
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
    Almazi JG; Alomari M; Belov L; Best OG; Shen Y; Graham ME; Mulligan SP; Christopherson RI
    Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):314-320. PubMed ID: 34886743
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Exploring the atr-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
    Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
    Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.
    Ye S; Wu J; Yao L; He J
    J Clin Pathol; 2022 Nov; 75(11):776-781. PubMed ID: 34348985
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
    Ding H; Vincelette ND; McGehee CD; Kohorst MA; Koh BD; Venkatachalam A; Meng XW; Schneider PA; Flatten KS; Peterson KL; Correia C; Lee SH; Patnaik M; Webster JA; Ghiaur G; Smith BD; Karp JE; Pratz KW; Li H; Karnitz LM; Kaufmann SH
    Cancer Res; 2021 May; 81(10):2666-2678. PubMed ID: 33414171
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.